Nitric oxide in rostral ventrolateral medulla regulates cardiac-sympathetic reflexes: role of synthase isoforms.
Our previous studies have shown that nitric oxide (NO) synthase (NOS)-containing neurons in the rostral ventrolateral medulla (rVLM) are activated during cardiac sympathoexcitatory reflexes (Refs. 12 and 13). However, the precise function of NO in the rVLM in regulation of these reflexes has not been defined. Three isoforms of NOS, including neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS), are located in the rVLM. We explored the role of NO, derived from different NOS isoforms in the rVLM, in processing cardiac-sympathetic reflexes using whole animal reflex and electrophysiological approaches. We found that, in anesthetized cats, increased mean arterial blood pressure and renal sympathetic nerve activity elicited by epicardial application of bradykinin (BK; 1-10 microg/ml, 50 microl) were significantly attenuated following unilateral rVLM microinjection of the nonselective NOS inhibitor, N(omega)-nitro-L-arginine methyl ester (50 nmol/50 nl), or a specific nNOS inhibitor, 7-nitroindazole (7-NI; 5-10 pmol/50 nl; both P < 0.05). In contrast, the responses of mean arterial blood pressure and renal sympathetic nerve activity to cardiac BK stimulation were unchanged by unilateral rVLM microinjection of N(omega)-nitro-D-arginine methyl ester (inactive isomer of N(omega)-nitro-L-arginine methyl ester, 50 nmol/50 nl), 3-6% methanol (7-NI vehicle), N(6)-(1-iminoethyl)-L-lysine (250 pmol/50 nl; iNOS inhibitor), or N(5)-(1-iminoethyl)-L-ornithine (250 nmol/50 nl; eNOS inhibitor). Furthermore, in separate cats, we noted that iontophoresis of 7-NI (0.1 mM) reduced the increased discharge of cardiovascular sympathoexcitatory rVLM neurons in response to cardiac stimulation with BK (P < 0.05). These neurons were characterized by their responses to inputs from baroreceptors, and their cardiac rhythmicity was determined through frequency and time domain analyses, correlating their discharge to arterial blood pressure and cardiac sympathetic efferent nerve activity. These data suggest that NO, specifically nNOS, mediates sympathetic cardiac-cardiovascular responses through its action in the rVLM.
Guo
Zhi-Ling
ZL
Department of Medicine, School of Medicine, University of California, Susan-Samueli Center for Integrative Medicine, Irvine, Irvine, California 92697-4075, USA. zguo@uci.edu
Tjen-A-Looi
Stephanie C
SC
Fu
Liang-Wu
LW
Longhurst
John C
JC
D000200:Action Potentials; D000818:Animals; D017704:Baroreflex / Q000187:drug effects; D001794:Blood Pressure; D001920:Bradykinin / Q000378:metabolism; D002415:Cats; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005260:Female; D006321:Heart / Q000294:innervation*; D007276:Injections, Intraventricular; D007478:Iontophoresis; D007527:Isoenzymes; D007668:Kidney / Q000294:innervation; D008297:Male; D008526:Medulla Oblongata / Q000166:cytology / Q000187:drug effects / Q000201:enzymology*; D026602:Nitrergic Neurons / Q000187:drug effects / Q000201:enzymology*; D009569:Nitric Oxide / Q000378:metabolism*; D052248:Nitric Oxide Synthase Type I / Q000037:antagonists & inhibitors / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010496:Pericardium / Q000378:metabolism; D010507:Periodicity; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000201:enzymology*
D004791:Enzyme Inhibitors; D007527:Isoenzymes; D009569:Nitric Oxide; D052248:Nitric Oxide Synthase Type I; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D001920:Bradykinin
Neurosci Lett. 2001 Sep 14;310(2-3):121-4
11585582
Am J Physiol Heart Circ Physiol. 2000 Nov;279(5):H2549-57
11045993
Br J Pharmacol. 2000 Mar;129(5):859-64
10696082
Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3627-35
17890425
Am J Physiol Heart Circ Physiol. 2001 Nov;281(5):H2010-7
11668062
J Neurophysiol. 1985 Dec;54(6):1498-512
4087045
Auton Neurosci. 2003 Jul 31;106(2):119-31
12878081
Brain Res. 1993 Feb 19;603(2):328-32
7681720
Circulation. 2001 Oct 2;104(14):1676-81
11581148
J Neurophysiol. 1997 Jan;77(1):65-75
9120597
Mol Pharmacol. 2003 Aug;64(2):521-32
12869658
Adv Pharmacol. 1995;34:171-86
8562433
Am J Physiol. 1995 Apr;268(4 Pt 2):R958-62
7733407
Hypertension. 1997 Sep;30(3 Pt 2):704-7
9323009
Br J Pharmacol. 2003 Feb;138(4):584-93
12598412
Circulation. 1983 Apr;67(4):796-801
6825235
Am J Physiol. 1990 Sep;259(3 Pt 2):R549-60
2118732
Clin Exp Pharmacol Physiol. 2001 Mar;28(3):155-63
11207669
Neuroscience. 2003;116(1):167-78
12535950
Prog Brain Res. 1989;81:105-16
2616776
Br J Pharmacol. 2001 Jun;133(4):606-14
11399678
Am J Physiol. 1986 May;250(5 Pt 2):R815-22
3706568
Hypertension. 1996 Jan;27(1):36-42
8591885
Brain Res. 1997 Aug 1;764(1-2):265-8
9295222
Am J Hypertens. 2000 Oct;13(10):1125-34
11041168
Am J Physiol Heart Circ Physiol. 2007 Apr;292(4):H1868-75
17158649
Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2530-40
18952714
Brain Res. 2002 Jan 18;925(1):55-66
11755900
Hypertension. 2001 Oct;38(4):896-901
11641305
Am J Physiol. 1995 May;268(5 Pt 2):H2114-24
7771562
J Physiol. 1998 Jul 15;510 ( Pt 2):633-41
9706010
J Biomed Sci. 2003 May-Jun;10(3):285-91
12711855
J Hypertens. 1996 Nov;14(11):1317-24
8934360
Brain Res. 1997 May 16;757(1):155-8
9200511
Neuroreport. 2006 Feb 27;17(3):255-9
16462593
J Physiol. 2001 Mar 1;531(Pt 2):445-58
11230517
Br J Pharmacol. 1990 Nov;101(3):746-52
1706208
Am J Physiol. 1997 Jun;272(6 Pt 2):H2843-51
9227564